# PLK4

## Overview
Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase encoded by the PLK4 gene, playing a pivotal role in centriole duplication, a critical process for maintaining genomic stability and proper cell division. As a member of the polo-like kinase family, PLK4 is characterized by its unique structure, which includes a kinase domain and three Polo-box domains that facilitate its function through dimerization and interaction with other proteins (Hoffmann2022Role; Klebba2015Autoinhibition). The protein's activity is tightly regulated by mechanisms such as autophosphorylation and ubiquitination, which ensure precise control over centriole numbers and prevent chromosomal instability (Holland2010Pololike; Sillibourne2010Autophosphorylation). Dysregulation of PLK4 is implicated in various cancers and developmental disorders, highlighting its significance as a potential therapeutic target (Shinmura2014PLK4; Dinçer2017Analysis).

## Structure
PLK4 is a serine/threonine protein kinase involved in centriole duplication. Its primary structure includes a kinase domain and a unique arrangement of three Polo-box domains (PB1, PB2, and PB3), which are crucial for its function, including dimerization and autoinhibition relief (Hoffmann2022Role; Klebba2015Autoinhibition). The secondary structure of PLK4 features alpha helices and beta sheets, typical of protein kinases, although specific details are not provided in the context.

The tertiary structure involves the folding of these domains, with the Polo-box domains serving as hubs for protein interaction and substrate binding (Klebba2015Autoinhibition). The quaternary structure of PLK4 includes its ability to form stable homodimers, which is essential for its recruitment to the centrosome and subsequent centriole duplication (Hoffmann2022Role).

PLK4 undergoes several post-translational modifications, including phosphorylation and acetylation. Phosphorylation is crucial for its activity and regulation, particularly in the activation loop and other regions, which modulate its interaction with regulatory proteins like Slimb (Klebba2015Autoinhibition). Acetylation by KAT2A/2B at lysine residues K45 and K46 affects its structural dynamics and inhibits its kinase activity, preventing centrosome amplification (Fournier2016KAT2AKAT2Btargeted). The context does not provide specific information on splice variant isoforms of PLK4.

## Function
Polo-like kinase 4 (PLK4) is a serine/threonine-protein kinase that plays a critical role in centriole duplication, a process essential for maintaining the correct number of centrosomes in human cells. PLK4 localizes to the centrosome, where it regulates the formation of new centrioles adjacent to preexisting ones, ensuring proper mitotic spindle formation and genomic stability (Holland2010Pololike; Guderian2010Plk4). 

The activity of PLK4 is tightly regulated through autophosphorylation, which promotes its own degradation via the SCF β-TrCP E3 ubiquitin ligase complex. This autoregulatory mechanism prevents centrosome overduplication by limiting PLK4's stability and activity, thereby maintaining proper centriole numbers and preventing chromosomal instability (Holland2010Pololike; Sillibourne2010Autophosphorylation). 

PLK4's kinase activity is crucial for its function, as it facilitates the phosphorylation of specific degron motifs, leading to its recognition and degradation by the proteasome (Guderian2010Plk4). In healthy human cells, PLK4 is inactive during the G1 phase but becomes active at the G1/S boundary, continuing through G2 and mitosis to ensure accurate cell division and genomic stability (Sillibourne2010Pololike).

## Clinical Significance
Mutations and dysregulation of the PLK4 gene are associated with several diseases and conditions due to its critical role in maintaining genomic stability. Overexpression of PLK4 is linked to various cancers, including gastric cancer, where it induces centrosome amplification and chromosomal instability, contributing to cancer pathogenesis (Shinmura2014PLK4). In colorectal cancer, PLK4 overexpression is also observed, while in hepatocellular carcinoma, its expression can be downregulated, leading to genomic instability (Zhang2021PoloLike). In breast cancer, cervical cancer, lung cancer, osteosarcoma, and melanoma, PLK4 overexpression is associated with poor prognosis and aggressive disease, often due to centrosome amplification and chromosomal instability (Zhang2021PoloLike).

PLK4 mutations are implicated in Seckel syndrome, a condition characterized by growth retardation and microcephaly. A specific mutation in PLK4 disrupts splicing, leading to a frameshift and premature translation termination, which significantly reduces functional PLK4 protein levels. This results in abnormalities in centriole biogenesis and mitotic spindle formation, contributing to the developmental defects observed in Seckel syndrome (Dinçer2017Analysis). These findings underscore the importance of PLK4 in both cancer development and developmental disorders.

## Interactions
PLK4 (polo like kinase 4) is involved in various protein interactions that are crucial for its function in centriole duplication and cellular stress responses. PLK4 interacts with stress-responsive MAPKKKs, such as MTK1 and TAK1, which phosphorylate PLK4 at the T170 site, essential for its activation under stress conditions (Nakamura2013SAPK). This phosphorylation primarily occurs in the cytoplasm and is mediated by TAK1 in response to osmotic stress or TNFα (Nakamura2013SAPK).

PLK4 also interacts with the SCF Slimb ubiquitin ligase, which regulates its levels through ubiquitination, preventing centriole reduplication (Rogers2009The). The interaction with βTrCP, another ubiquitin ligase, is mediated by a DSG motif in PLK4, which requires phosphorylation for binding, leading to PLK4's degradation (Guderian2010Plk4).

In the context of inflammasome regulation, PLK4 binds to Spata2 and CYLD, inhibiting NLRP3 inflammasome activation. It phosphorylates NEK7 at Ser204, suppressing its interaction with NLRP3 (Yang2019PLK). PLK4 also interacts with the Arp2/3 complex, specifically phosphorylating Arp2, which is crucial for cancer cell migration and invasion (Kazazian2017Plk4). These interactions highlight PLK4's multifaceted role in cellular processes and its potential as a therapeutic target.


## References


[1. (Yang2019PLK) Xiao‐Dong Yang, Wenguo Li, Shuangyan Zhang, Dandan Wu, Xiaoli Jiang, Rong Tan, Xiaoyin Niu, Qijun Wang, Xuefeng Wu, Zhiduo Liu, Lin‐Feng Chen, Jun Qin, and Bing Su. <scp>plk</scp> 4 deubiquitination by spata2‐cyld suppresses nek7‐mediated nlrp3 inflammasome activation at the centrosome. The EMBO Journal, November 2019. URL: http://dx.doi.org/10.15252/embj.2019102201, doi:10.15252/embj.2019102201. This article has 56 citations.](https://doi.org/10.15252/embj.2019102201)

[2. (Klebba2015Autoinhibition) Joseph E. Klebba, Daniel W. Buster, Tiffany A. McLamarrah, Nasser M. Rusan, and Gregory C. Rogers. Autoinhibition and relief mechanism for polo-like kinase 4. Proceedings of the National Academy of Sciences, February 2015. URL: http://dx.doi.org/10.1073/pnas.1417967112, doi:10.1073/pnas.1417967112. This article has 68 citations.](https://doi.org/10.1073/pnas.1417967112)

[3. (Fournier2016KAT2AKAT2Btargeted) Marjorie Fournier, Meritxell Orpinell, Cédric Grauffel, Elisabeth Scheer, Jean-Marie Garnier, Tao Ye, Virginie Chavant, Mathilde Joint, Fumiko Esashi, Annick Dejaegere, Pierre Gönczy, and László Tora. Kat2a/kat2b-targeted acetylome reveals a role for plk4 acetylation in preventing centrosome amplification. Nature Communications, October 2016. URL: http://dx.doi.org/10.1038/ncomms13227, doi:10.1038/ncomms13227. This article has 80 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms13227)

[4. (Guderian2010Plk4) Gernot Guderian, Jens Westendorf, Andreas Uldschmid, and Erich A. Nigg. Plk4 trans-autophosphorylation regulates centriole number by controlling βtrcp-mediated degradation. Journal of Cell Science, 123(13):2163–2169, July 2010. URL: http://dx.doi.org/10.1242/jcs.068502, doi:10.1242/jcs.068502. This article has 182 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.068502)

[5. (Kazazian2017Plk4) Karineh Kazazian, Christopher Go, Hannah Wu, Olga Brashavitskaya, Roland Xu, James W. Dennis, Anne-Claude Gingras, and Carol J. Swallow. Plk4 promotes cancer invasion and metastasis through arp2/3 complex regulation of the actin cytoskeleton. Cancer Research, 77(2):434–447, January 2017. URL: http://dx.doi.org/10.1158/0008-5472.CAN-16-2060, doi:10.1158/0008-5472.can-16-2060. This article has 148 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.CAN-16-2060)

[6. (Hoffmann2022Role) Ingrid Hoffmann. Role of polo-like kinases plk1 and plk4 in the initiation of centriole duplication—impact on cancer. Cells, 11(5):786, February 2022. URL: http://dx.doi.org/10.3390/cells11050786, doi:10.3390/cells11050786. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells11050786)

[7. (Sillibourne2010Autophosphorylation) James E. Sillibourne, Frederik Tack, Nele Vloemans, An Boeckx, Sathiesan Thambirajah, Pascal Bonnet, Frans C.S. Ramaekers, Michel Bornens, and Thierry Grand-Perret. Autophosphorylation of polo-like kinase 4 and its role in centriole duplication. Molecular Biology of the Cell, 21(4):547–561, February 2010. URL: http://dx.doi.org/10.1091/mbc.E09-06-0505, doi:10.1091/mbc.e09-06-0505. This article has 145 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.E09-06-0505)

[8. (Rogers2009The) Gregory C. Rogers, Nasser M. Rusan, David M. Roberts, Mark Peifer, and Stephen L. Rogers. The scfslimb ubiquitin ligase regulates plk4/sak levels to block centriole reduplication. Journal of Cell Biology, 184(2):225–239, January 2009. URL: http://dx.doi.org/10.1083/jcb.200808049, doi:10.1083/jcb.200808049. This article has 214 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1083/jcb.200808049)

[9. (Nakamura2013SAPK) Takanori Nakamura, Haruo Saito, and Mutsuhiro Takekawa. Sapk pathways and p53 cooperatively regulate plk4 activity and centrosome integrity under stress. Nature Communications, April 2013. URL: http://dx.doi.org/10.1038/ncomms2752, doi:10.1038/ncomms2752. This article has 71 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms2752)

[10. (Dinçer2017Analysis) Tuba Dinçer, Gülden Yorgancıoğlu-Budak, Akgün Ölmez, İdris Er, Yavuz Dodurga, Özmert MA Özdemir, Bayram Toraman, Adem Yıldırım, Nuran Sabir, Nurten A Akarsu, C Nur Semerci, and Ersan Kalay. Analysis of centrosome and dna damage response in plk4 associated seckel syndrome. European Journal of Human Genetics, 25(10):1118–1125, August 2017. URL: http://dx.doi.org/10.1038/ejhg.2017.120, doi:10.1038/ejhg.2017.120. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2017.120)

[11. (Sillibourne2010Pololike) James E Sillibourne and Michel Bornens. Polo-like kinase 4: the odd one out of the family. Cell Division, 5(1):25, 2010. URL: http://dx.doi.org/10.1186/1747-1028-5-25, doi:10.1186/1747-1028-5-25. This article has 65 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1747-1028-5-25)

[12. (Shinmura2014PLK4) Kazuya Shinmura, Nobuya Kurabe, Masanori Goto, Hidetaka Yamada, Hiroko Natsume, Hiroyuki Konno, and Haruhiko Sugimura. Plk4 overexpression and its effect on centrosome regulation and chromosome stability in human gastric cancer. Molecular Biology Reports, 41(10):6635–6644, July 2014. URL: http://dx.doi.org/10.1007/s11033-014-3546-2, doi:10.1007/s11033-014-3546-2. This article has 45 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11033-014-3546-2)

[13. (Holland2010Pololike) Andrew J. Holland, Weijie Lan, Sherry Niessen, Heather Hoover, and Don W. Cleveland. Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability. Journal of Cell Biology, 188(2):191–198, January 2010. URL: http://dx.doi.org/10.1083/jcb.200911102, doi:10.1083/jcb.200911102. This article has 243 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1083/jcb.200911102)

[14. (Zhang2021PoloLike) Xiaoyang Zhang, Cheng Wei, Hao Liang, and Lei Han. Polo-like kinase 4’s critical role in cancer development and strategies for plk4-targeted therapy. Frontiers in Oncology, March 2021. URL: http://dx.doi.org/10.3389/fonc.2021.587554, doi:10.3389/fonc.2021.587554. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.587554)